Commave Therapeutics SA Deal History & Licensing Activity
Commave Therapeutics SA is a life sciences. Over the past three years, Commave Therapeutics SA has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Neurology
Commave Therapeutics SA Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Commave Therapeutics SA in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| serdexmethylphenidate (SDX) portfolio | Zevra Therapeutics | Small Molecules | Approved | acquisition | Mar 2026 |
Commave Therapeutics SA Pipeline Focus
Therapeutic areas and modalities where Commave Therapeutics SA is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Commave Therapeutics SA's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Commave Therapeutics SA Licensing & Deal Activity
Commave Therapeutics SA is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Commave Therapeutics SA ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Commave Therapeutics SA include Neurology (2 deals and trials). In terms of modality, Commave Therapeutics SA has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Commave Therapeutics SA and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Commave Therapeutics SA's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.